ClinicalTrials.gg
CompletedNCT04936542DIRECTIONUpdated Jul 9, 2026Results posted

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

A Phase 4 interventional study of AboBoNT-A and OnaBoNT-A in Upper Limb Spasticity, sponsored by Ipsen. Completed at 76 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Ipsen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
464
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each product.

02

Conditions studied

  • Upper Limb Spasticity
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 80 years of age inclusive, at the time of signing the
  • 2a. [US/France] Participants with stable Upper Limb Spasticity (ULS) for at least 3 months, in whom treatment of only one upper limb is necessary for the duration of the study;
  • 2b. [Canada] Participants with stable post-stroke ULS for at least 3 months, in whom treatment of only one upper limb is necessary for the duration of the study
  • Participants who are either naïve to Botulinum toxin type A (BoNT-A) for ULS or who have been previously treated with BoNT-A for ULS;
  • Participants with MAS score of at least 2 at two muscle groups (one of these two muscles groups should be the PTMG) and at least 1 in the remaining muscle group.
  • Participants with DAS score of at least 2 on the Principal Target of Treatment () (one of four functional domains: dressing, hygiene, limb position and pain);
  • Participants who require BoNT-A injection in all of the following muscles: flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis and biceps brachii;
  • Participants for whom injection of a total dose of 900 Units aboBoNT-A or 360 Units onaBoNT-A is considered by the investigator to be clinically appropriate;
  • Participants who have been stable for at least 3 months prior to study entry in terms of oral antispasticity, anticoagulant and/or anticholinergic medication if treated are considered by the investigator likely to remain stable for the duration of the study;

    • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
    • Male participants: Male participants must agree that, if their partner is at risk of becoming pregnant, they will use an effective method of contraception. The participants must agree to use the contraception during the whole period of the study.
    • Female participants:A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
  • Is a woman of non-, defined as for at least

    1 year; surgical sterilisation at least 3 months before entering the study; or hysterectomy. or

  • Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method during the entire study period.A WOCBP must have a negative highly sensitive pregnancy test at screening (urine or serum) as required by local regulations.

Exclusion criteria

Exclusion Criteria:

  • Major limitations in the passive range of motion in the paretic upper limb;
  • Major neurological impairment (other than limb paresis) that could negatively affect functional performance;
  • Participants clinically requiring injection into any upper limb muscles other than the five muscles of one arm listed in Section 5.1, or requiring injection into both arms or any lower limb within the timeframe of the study;
  • to any BoNT product or ;
  • Hypersensitivity to cow's milk protein (casein);
  • Infection at the proposed injection site(s);
  • Known peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (e.g. myasthenia gravis or Lambert-Eaton syndrome);
  • Any medical condition (including dysphagia or breathing difficulties/compromised respiratory function) that in the opinion of the investigator, might jeopardize the participant's safety;

    • abnormal screening/baseline findings or any other medical condition(s) that, in the opinion of the investigator, might jeopardise the participant's safety
  • Women who are pregnant or lactating

    • In the clinical judgement of the investigator, BoNT treatment is inappropriate
    • BoNT naïve participants with a history of facial neurogenic disorder (facial paralysis, polyradiculoneuropathy) (only for France)
  • Participants treated with BoNT of any type for any indication (e.g. bladder injection, headache or cosmetic) within the previous 12 weeks or planned/likely to be treated during the course of the study;
  • Prior history of non-responsiveness to BoNT treatment;
  • Previous surgery, or administration of alcohol or phenol in the study limb 6 months or earlier from study enrolment or planned/likely to be treated during the course of the study;
  • Participants treated with intrathecal baclofen (except if treatment has reached a stable dose for >4 weeks and is likely to remain stable throughout the study), aminoglycosides or other agents interfering with neuromuscular transmission (e.g. curare-like agents) within the 4 weeks prior to study enrolment or planned/likely to be treated during the course of the study
  • Participants receiving concomitant medication treatment with the following PT/OT interventions on the study limb: new splinting/orthotics/casting, serial casting, shockwave therapy, dry needling and needle tenotomies. However, PT/OT interventions not intended to reduce study limb spasticity (e.g. functional training exercises) or with a transient (\<1 day) reduction of study limb spasticity (e.g. stretching, weight bearing) are allowed.

    • Participants previously randomised for this study
    • Participants unwilling or unable to understand the nature, scope and possible consequences of the study and to comply with study procedures and requirements
    • Participants currently enrolled in any other clinical study or have participated in one within the 12 weeks (or 5 half-lives of the product of that study, whichever is longer) prior to enrolment/inclusion visit, or are scheduled to receive a new investigational drug while the study is ongoing
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
464 participants (actual)

Study arms

  • Other
    Sequence 1

    Participants will receive one cycle of aboBoNT-A followed by one cycle of onaBoNT-A in the selected overactive upper limb muscles

    Biological: AboBoNT-A · Biological: OnaBoNT-A

  • Other
    Sequence 2

    Participants will receive one cycle of onaBoNT-A followed by one cycle of aboBoNT-A in the selected overactive upper limb muscles

    Biological: AboBoNT-A · Biological: OnaBoNT-A

Interventions

  • BiologicalAboBoNT-A

    AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)

    Also known as: Dysport®

  • BiologicalOnaBoNT-A

    OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)

    Also known as: Botox®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) From Injection to 12 Weeks

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A TEAE was defined for each treatment cycle as any AE that occurred during the cycle if it was not present prior to treatment injection, or it was present prior to treatment injection but the intensity increased during the cycle. Percentage of participants with TEAEs that occurred during each cycle from injection to 12 weeks after injection (until 84 days after injection or until the day prior to next injection day or until end of study/early withdrawal day whichever occurred first) is presented. Percentages are rounded off to the tenth decimal place.

    Time frame: From Baseline (Injection: Day 1) up to 12 weeks

Secondary outcomes

  1. Number of Participants With Adverse Drug Reactions (ADRs), Treatment-Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) From Injection to 12 Weeks

    AE: any untoward medical occurrence in a clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. SAE: any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via an authorized medicinal product, or any other medically important event. TEAE for each treatment cycle: any AE that occurred during cycle if it was not present prior to treatment injection, or it was present prior to treatment injection but intensity increased during cycle. ADR: any TEAE that was assessed by Investigator as related to study treatment. AESI: TEAE that suggested a possible remote spread of toxin or events suggestive of hypersensitivity like reactions.

    Time frame: From Baseline (Injection: Day 1) up to 12 weeks

  2. Adjusted Least Square Mean of Duration of Response Based on Retreatment Criteria

    The duration of response was defined for Cycle 1 as time between Cycle 1 injection and the first Cycle 1 visit when retreatment criteria were met (from Week 10 visit), or time between Cycle 1 injection and study withdrawal if the participant discontinued from the study before Cycle 2 injection without meeting retreatment criteria; for Cycle 2 as time between Cycle 2 injection and the first Cycle 2 visit when retreatment criteria were met (from Week 10 visit), or time between Cycle 2 injection and end of study if the participant completed the study or discontinued from the study after Cycle 2 injection without meeting retreatment criteria. It was calculated as the date of retreatment criteria met or withdrawal date (or last visit date for lost to follow-up participants) or completion date - date of injection + 1.

    Time frame: Baseline (Day 1) up to Week 10 (earliest) if retreatment criteria were met, or up to Week 24 (latest) if retreatment criteria were not met

  3. Adjusted Least Square Mean of Muscle Tone Assessed by the Modified Ashworth Scale (MAS) for Finger, Wrist and Elbow Flexors Based on Primary Target Muscle Group (PTMG) at Week 12

    Muscle tone for finger, wrist, elbow flexors assessed with MAS tool using scale: 0= no increase in muscle tone, 1= slight increase in muscle tone, manifested by a catch and release or by minimal resistance at end of range of motion (ROM) when affected part(s) was moved in flexion or extension, 1+= slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout remainder of ROM, 2= more marked increase in muscle tone through most of ROM, but affected part(s) easily moved, 3= considerable increase in muscle tone, passive movement difficult, 4= affected part(s) rigid in flexion or extension. PTMG included finger, wrist or elbow flexors which were selected by Investigators at screening as muscle group with highest MAS score. MAS total score was calculated as the sum of scores for all 3 joints (finger, wrist, elbow), ranged from: 0 (best) to 12 (worst); higher scores indicated worse outcomes.

    Time frame: Week 12 (Cycles 1 and 2; each cycle was 12 to 24 weeks)

  4. Adjusted Least Square Mean of Perceived Function and Pain Assessed by the Disability Assessment Scale (DAS) Based on Principal Target of Treatment (PTT) at Week 12

    The DAS was used to determine the extent of functional impairment in 4 domains: hygiene, dressing, limb position and pain. Impairment was assessed on a 4-point scale: 0= no disability, 1= mild disability (noticeable but did not interfere significantly with normal activities), 2= moderate disability (normal activities required increased effort and/or assistance) and 3= severe disability (normal activities limited). The 4 domain ratings were added to obtain DAS total score which ranged between 0 (best) and 12 (worst); higher scores indicated severe disability. The PTT was defined at screening as 1 of the 4 domains, with an associated DAS score for assessment.

    Time frame: Week 12 (Cycles 1 and 2; each cycle was 12 to 24 weeks)

  5. Adjusted Least Square Mean of Physician Global Assessment (PGA) of Treatment Response at Week 12

    The PGA of treatment response was assessed by asking the Investigator the following question: 'how would you rate the response to treatment in the participant's upper limb since the last injection?' and answered on a 9-point rating scale (-4: markedly worse, -3: much worse, -2: worse, -1: slightly worse, 0: no change, +1: slightly improved, +2: improved, +3: much improved and +4: markedly improved). Higher scores indicate greater better outcomes. 'Any improvement' in PGA was defined by a score including: +1, +2, +3 and +4.

    Time frame: Week 12 (Cycles 1 and 2; each cycle was 12 to 24 weeks)

  6. Change From Baseline to Weeks 4, 12 and 24 (End of Cycle) in Quality of Life (QoL) Assessed by the 12-Item Short Form (SF-12) Health Survey Perceived Health Score: Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) Scores

    SF-12 consisted of 12 questions \& asked respondent to answer questions as they pertained to way he/she felt or acted during past week. SF-12 covered 8 domains of health:physical functioning(PF),role physical(RP),bodily pain(BP),general health(GH),vitality(VT),social functioning(SF),role emotional(RE) \& mental health(MH). Score range for each of 8 domains:0(maximum disability) to 100(no disability);higher scores:good QoL. Responses on SF-12 were used to obtain 2 summary scores:PCS-12 contributed by PF,RP,BP, and GH and MCS-12 contributed by MH,RE,SF and VT. Summations of item scores of same domains gave sub-scale scores,which were transformed to obtain summary scores of PCS-12 \& MCS-12. Both PCS-12 \& MCS-12 scores ranged from 0(worst) to 100(best);higher scores:better QoL.Baseline:last non-missing measurement prior to first study treatment administration.Change from baseline in QoL assessed by SF-12 health survey perceived health score based on PCS-12 and MCS-12 scores is presented.

    Time frame: Baseline (Day 1) and Weeks 4, 12, and 24 (end of cycle) (Cycles 1 and 2; each cycle was 12 to 24 weeks)

  7. Change From Baseline to Weeks 4, 12 and 24 (End of Cycle) in Quality of Life Assessed by the Spasticity-Related Quality of Life Tool (SQoL-6D)

    The SQoL-6D questionnaire was a brief questionnaire in 6 domains: pain/discomfort, involuntary movements or spasms, restricted range of movement, caring for the affected limb, using the affected limb and mobility/balance which was designed to assess QoL in relation to spasticity that affected the upper limb, which included the arm, shoulder or hand. Each dimension was assessed by asking participants about symptoms within the last 7 days, using a 5-level scale ranging from 0 (best) to 4 (worst); higher scores indicated worse condition. The mean of the 6-dimension scores was calculated to obtain the total score which ranged from 0 (worse) to 100 (best); higher score indicated better QoL. Baseline was defined as the last non-missing measurement prior to first study treatment administration. Change from Baseline in QoL assessed by SQoL-6D is presented.

    Time frame: Baseline (Day 1) and Weeks 4, 12, and 24 (end of Cycle) (Cycles 1 and 2; each cycle was 12 to 24 weeks)

07

Results

Posted Jul 9, 2026

Participant flow

This post-marketing, randomized, double-blind, crossover study was conducted in participants with upper limb spasticity.

Cycle 1 (Day 1 to Weeks 12 or 24)
Participant flow — Cycle 1 (Day 1 to Weeks 12 or 24)
MilestoneaboBoNT-A Followed by onaBoNT-AonaBoNT-A Followed by aboBoNT-A
Started231233
Entered cycle 1 (injected)228231
Completed193200
Not completed3833
Withdrew: Withdrawal by subject108
Withdrew: Adverse event22
Withdrew: Protocol deviation01
Withdrew: Physician decision149
Withdrew: Lost to follow-up35
Withdrew: Death10
Withdrew: Lack of efficacy11
Withdrew: Technical problems22
Withdrew: Other23
Withdrew: Randomized but not injected32
Cycle 2 (Day 1 to Weeks 12 or 24)
Participant flow — Cycle 2 (Day 1 to Weeks 12 or 24)
MilestoneaboBoNT-A Followed by onaBoNT-AonaBoNT-A Followed by aboBoNT-A
Started193200
Completed170174
Not completed2326
Withdrew: Withdrawal by subject611
Withdrew: Adverse event10
Withdrew: Protocol deviation10
Withdrew: Physician decision01
Withdrew: Lost to follow-up67
Withdrew: Death10
Withdrew: Other87

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) From Injection to 12 Weeks

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A TEAE was defined for each treatment cycle as any AE that occurred during the cycle if it was not present prior to treatment injection, or it was present prior to treatment injection but the intensity increased during the cycle. Percentage of participants with TEAEs that occurred during each cycle from injection to 12 weeks after injection (until 84 days after injection or until the day prior to next injection day or until end of study/early withdrawal day whichever occurred first) is presented. Percentages are rounded off to the tenth decimal place.

Time frame:
From Baseline (Injection: Day 1) up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) From Injection to 12 Weeks
percentage of participantsaboBoNT-AonaBoNT-A
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) From Injection to 12 Weeks20.3 (17.6 to 23.0)23.0 (20.1 to 25.8)
Statistical analysis
  • aboBoNT-A vs onaBoNT-A · Difference in percentage of participants: -2.7 · 80% CI -6.2 to 0.9Generalized linear mixed model with binomial distribution and identity link.
SecondaryNumber of Participants With Adverse Drug Reactions (ADRs), Treatment-Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) From Injection to 12 Weeks

AE: any untoward medical occurrence in a clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. SAE: any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via an authorized medicinal product, or any other medically important event. TEAE for each treatment cycle: any AE that occurred during cycle if it was not present prior to treatment injection, or it was present prior to treatment injection but intensity increased during cycle. ADR: any TEAE that was assessed by Investigator as related to study treatment. AESI: TEAE that suggested a possible remote spread of toxin or events suggestive of hypersensitivity like reactions.

Time frame:
From Baseline (Injection: Day 1) up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Drug Reactions (ADRs), Treatment-Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) From Injection to 12 Weeks
ParticipantsaboBoNT-AonaBoNT-A
ADRs1515
TESAEs1618
AESIs64
SecondaryAdjusted Least Square Mean of Duration of Response Based on Retreatment Criteria

The duration of response was defined for Cycle 1 as time between Cycle 1 injection and the first Cycle 1 visit when retreatment criteria were met (from Week 10 visit), or time between Cycle 1 injection and study withdrawal if the participant discontinued from the study before Cycle 2 injection without meeting retreatment criteria; for Cycle 2 as time between Cycle 2 injection and the first Cycle 2 visit when retreatment criteria were met (from Week 10 visit), or time between Cycle 2 injection and end of study if the participant completed the study or discontinued from the study after Cycle 2 injection without meeting retreatment criteria. It was calculated as the date of retreatment criteria met or withdrawal date (or last visit date for lost to follow-up participants) or completion date - date of injection + 1.

Time frame:
Baseline (Day 1) up to Week 10 (earliest) if retreatment criteria were met, or up to Week 24 (latest) if retreatment criteria were not met
Reported as:
Least squares mean · days
Adjusted Least Square Mean of Duration of Response Based on Retreatment Criteria
daysaboBoNT-AonaBoNT-A
Adjusted Least Square Mean of Duration of Response Based on Retreatment Criteria99.3 (96.7 to 101.6)96.3 (93.9 to 98.5)
Statistical analysis
  • aboBoNT-A vs onaBoNT-A · Final model · p = 0.1714 · Difference of least square means: 3.03 · 80% CI 0.19 to 5.88
SecondaryAdjusted Least Square Mean of Muscle Tone Assessed by the Modified Ashworth Scale (MAS) for Finger, Wrist and Elbow Flexors Based on Primary Target Muscle Group (PTMG) at Week 12

Muscle tone for finger, wrist, elbow flexors assessed with MAS tool using scale: 0= no increase in muscle tone, 1= slight increase in muscle tone, manifested by a catch and release or by minimal resistance at end of range of motion (ROM) when affected part(s) was moved in flexion or extension, 1+= slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout remainder of ROM, 2= more marked increase in muscle tone through most of ROM, but affected part(s) easily moved, 3= considerable increase in muscle tone, passive movement difficult, 4= affected part(s) rigid in flexion or extension. PTMG included finger, wrist or elbow flexors which were selected by Investigators at screening as muscle group with highest MAS score. MAS total score was calculated as the sum of scores for all 3 joints (finger, wrist, elbow), ranged from: 0 (best) to 12 (worst); higher scores indicated worse outcomes.

Time frame:
Week 12 (Cycles 1 and 2; each cycle was 12 to 24 weeks)
Reported as:
Least squares mean · score on a scale
Adjusted Least Square Mean of Muscle Tone Assessed by the Modified Ashworth Scale (MAS) for Finger, Wrist and Elbow Flexors Based on Primary Target Muscle Group (PTMG) at Week 12
score on a scaleaboBoNT-AonaBoNT-A
Adjusted Least Square Mean of Muscle Tone Assessed by the Modified Ashworth Scale (MAS) for Finger, Wrist and Elbow Flexors Based on Primary Target Muscle Group (PTMG) at Week 122.4 (2.34 to 2.45)2.4 (2.39 to 2.49)
Statistical analysis
  • aboBoNT-A vs onaBoNT-A · Bonferroni-Adjusted · p = >0.9999 · Difference of least square means: -0.04 · 93.3% CI -0.12 to 0.05
SecondaryAdjusted Least Square Mean of Perceived Function and Pain Assessed by the Disability Assessment Scale (DAS) Based on Principal Target of Treatment (PTT) at Week 12

The DAS was used to determine the extent of functional impairment in 4 domains: hygiene, dressing, limb position and pain. Impairment was assessed on a 4-point scale: 0= no disability, 1= mild disability (noticeable but did not interfere significantly with normal activities), 2= moderate disability (normal activities required increased effort and/or assistance) and 3= severe disability (normal activities limited). The 4 domain ratings were added to obtain DAS total score which ranged between 0 (best) and 12 (worst); higher scores indicated severe disability. The PTT was defined at screening as 1 of the 4 domains, with an associated DAS score for assessment.

Time frame:
Week 12 (Cycles 1 and 2; each cycle was 12 to 24 weeks)
Reported as:
Least squares mean · score on a scale
Adjusted Least Square Mean of Perceived Function and Pain Assessed by the Disability Assessment Scale (DAS) Based on Principal Target of Treatment (PTT) at Week 12
score on a scaleaboBoNT-AonaBoNT-A
Adjusted Least Square Mean of Perceived Function and Pain Assessed by the Disability Assessment Scale (DAS) Based on Principal Target of Treatment (PTT) at Week 121.8 (1.8 to 1.9)1.8 (1.8 to 1.9)
Statistical analysis
  • aboBoNT-A vs onaBoNT-A · Bonferroni-Adjusted · p = >0.9999 · Difference of least square means: -0.00 · 93.3% CI -0.08 to 0.08
SecondaryAdjusted Least Square Mean of Physician Global Assessment (PGA) of Treatment Response at Week 12

The PGA of treatment response was assessed by asking the Investigator the following question: 'how would you rate the response to treatment in the participant's upper limb since the last injection?' and answered on a 9-point rating scale (-4: markedly worse, -3: much worse, -2: worse, -1: slightly worse, 0: no change, +1: slightly improved, +2: improved, +3: much improved and +4: markedly improved). Higher scores indicate greater better outcomes. 'Any improvement' in PGA was defined by a score including: +1, +2, +3 and +4.

Time frame:
Week 12 (Cycles 1 and 2; each cycle was 12 to 24 weeks)
Reported as:
Least squares mean · score on a scale
Adjusted Least Square Mean of Physician Global Assessment (PGA) of Treatment Response at Week 12
score on a scaleaboBoNT-AonaBoNT-A
Adjusted Least Square Mean of Physician Global Assessment (PGA) of Treatment Response at Week 120.7 (0.5 to 0.7)0.6 (0.5 to 0.7)
Statistical analysis
  • aboBoNT-A vs onaBoNT-A · Bonferroni-Adjusted · p = >0.9999 · Difference of least square means: 0.02 · 93.3% CI -0.12 to 0.16
SecondaryChange From Baseline to Weeks 4, 12 and 24 (End of Cycle) in Quality of Life (QoL) Assessed by the 12-Item Short Form (SF-12) Health Survey Perceived Health Score: Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) Scores

SF-12 consisted of 12 questions \& asked respondent to answer questions as they pertained to way he/she felt or acted during past week. SF-12 covered 8 domains of health:physical functioning(PF),role physical(RP),bodily pain(BP),general health(GH),vitality(VT),social functioning(SF),role emotional(RE) \& mental health(MH). Score range for each of 8 domains:0(maximum disability) to 100(no disability);higher scores:good QoL. Responses on SF-12 were used to obtain 2 summary scores:PCS-12 contributed by PF,RP,BP, and GH and MCS-12 contributed by MH,RE,SF and VT. Summations of item scores of same domains gave sub-scale scores,which were transformed to obtain summary scores of PCS-12 \& MCS-12. Both PCS-12 \& MCS-12 scores ranged from 0(worst) to 100(best);higher scores:better QoL.Baseline:last non-missing measurement prior to first study treatment administration.Change from baseline in QoL assessed by SF-12 health survey perceived health score based on PCS-12 and MCS-12 scores is presented.

Time frame:
Baseline (Day 1) and Weeks 4, 12, and 24 (end of cycle) (Cycles 1 and 2; each cycle was 12 to 24 weeks)
Reported as:
Mean · score on a scale
Change From Baseline to Weeks 4, 12 and 24 (End of Cycle) in Quality of Life (QoL) Assessed by the 12-Item Short Form (SF-12) Health Survey Perceived Health Score: Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) Scores
score on a scaleaboBoNT-AonaBoNT-A
Week 4: PCS-121.993 ± 7.1891.733 ± 7.581
Week 4: MCS-12-0.052 ± 10.4340.013 ± 9.609
Week 12: PCS-121.782 ± 7.1791.127 ± 7.626
Week 12: MCS-12-0.265 ± 10.056-0.325 ± 10.076
Week 24 (end of cycle): PCS-121.716 ± 7.2341.129 ± 7.840
Week 24 (end of cycle): MCS-12-0.089 ± 10.300-0.448 ± 9.902
SecondaryChange From Baseline to Weeks 4, 12 and 24 (End of Cycle) in Quality of Life Assessed by the Spasticity-Related Quality of Life Tool (SQoL-6D)

The SQoL-6D questionnaire was a brief questionnaire in 6 domains: pain/discomfort, involuntary movements or spasms, restricted range of movement, caring for the affected limb, using the affected limb and mobility/balance which was designed to assess QoL in relation to spasticity that affected the upper limb, which included the arm, shoulder or hand. Each dimension was assessed by asking participants about symptoms within the last 7 days, using a 5-level scale ranging from 0 (best) to 4 (worst); higher scores indicated worse condition. The mean of the 6-dimension scores was calculated to obtain the total score which ranged from 0 (worse) to 100 (best); higher score indicated better QoL. Baseline was defined as the last non-missing measurement prior to first study treatment administration. Change from Baseline in QoL assessed by SQoL-6D is presented.

Time frame:
Baseline (Day 1) and Weeks 4, 12, and 24 (end of Cycle) (Cycles 1 and 2; each cycle was 12 to 24 weeks)
Reported as:
Mean · score on a scale
Change From Baseline to Weeks 4, 12 and 24 (End of Cycle) in Quality of Life Assessed by the Spasticity-Related Quality of Life Tool (SQoL-6D)
score on a scaleaboBoNT-AonaBoNT-A
Week 49.69 ± 16.1810.38 ± 16.15
Week 128.10 ± 15.958.28 ± 15.38
Week 24 (end of cycle)7.21 ± 16.207.09 ± 15.85

Adverse events

Collected over TEAEs were collected from first dose of study drug (Day 1) up to 24 weeks after injection (Cycles 1 and 2; each cycle was 12 to 24 weeks). All-cause mortality (deaths) was collected from first dose of study drug (Day 1) to the end of follow-up for death for each participant, total follow-up for the study was approximately 217 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
aboBoNT-A1/427 (0.2%)21/427 (4.9%)0/427 (0%)
onaBoNT-A1/424 (0.2%)20/424 (4.7%)0/424 (0%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventaboBoNT-AonaBoNT-A
SeizureNervous system disorders5/4272/424
COVID-19Infections and infestations4/4270/424
Device related infectionInfections and infestations0/4272/424
PyelonephritisInfections and infestations2/4270/424
SyncopeNervous system disorders1/4271/424
Carotid artery stenosisNervous system disorders0/4271/424
Cerebrovascular accidentNervous system disorders0/4271/424
Middle cerebral artery strokeNervous system disorders0/4271/424
Cardiac arrestCardiac disorders1/4271/424
Acute left ventricular failureCardiac disorders0/4271/424

Baseline characteristics

The randomized set included all participants who were randomized to a treatment sequence.

Age, Continuous
Age, Continuous(years)aboBoNT-A Followed by onaBoNT-AonaBoNT-A Followed by aboBoNT-ATotal
Mean57.0 ± 12.556.5 ± 13.756.8 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)aboBoNT-A Followed by onaBoNT-AonaBoNT-A Followed by aboBoNT-ATotal
Female7979158
Male152154306
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)aboBoNT-A Followed by onaBoNT-AonaBoNT-A Followed by aboBoNT-ATotal
Hispanic or Latino433780
Not Hispanic or Latino155162317
Not Reported437
Missing011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)aboBoNT-A Followed by onaBoNT-AonaBoNT-A Followed by aboBoNT-ATotal
Asian8513
Black or African American4656102
White134132266
Native Hawaiian or Other Pacific Islander112
Multiple101
Not Reported213
Other9716
Missing112
08

Study locations

76 sites
  • University of Alabama
    Birmingham, Alabama 25233, United States
  • HonorHealth Scottsdale Osborn Medical Center
    Scottsdale, Arizona 85251, United States
  • Movement Disorders Center of Arizona
    Scottsdale, Arizona 85258, United States
  • The University of Arizona
    Tucson, Arizona 85724, United States
  • Rancho Los Amigos National Rehabilitation Center (RLANRC) - Neurology
    Downey, California 90242, United States
  • Parkinson's & Movement Disorders Institute
    Fountain Valley, California 92708, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • Loma Linda University Health Care
    Loma Linda, California 92350, United States
  • Southland Neurologic Institute
    Long Beach, California 90808, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Hasbani And Hasbani Medical Group
    New Haven, Connecticut 06511, United States
  • Ki Health Partners LLC D/B/A New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • First Choice Neurology
    Boca Raton, Florida 33428, United States
  • James A Haley Veterans Hospital
    Tampa, Florida 33612, United States
  • University of South Florida Health-Morsani Center for Advanced Healthcare
    Tampa, Florida 33612, United States
  • Emory University of School of Medicine
    Atlanta, Georgia 30322, United States
  • Hawaii Pacific Neuroscience
    Honolulu, Hawaii 96817, United States
  • Shirley Ryan Ability Lab
    Chicago, Illinois 60611-3167, United States
  • Fort Wayne Neurological Center
    Fort Wayne, Indiana 46804, United States
  • Kansas City Bone and Joint Clinic, P.A. (KCBJ) - Overland Pa
    Overland Park, Kansas 66211-1358, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • LSU Healthcare network
    New Orleans, Louisiana 70112, United States
  • UMass Memorial Medical Center - University Campus
    Worcester, Massachusetts 01655, United States
  • William Beaumont Hospital
    Dearborn, Michigan 48124, United States
  • Medical Rehabilitation Group, PC
    Grand Blanc, Michigan 48439, United States
  • Mary Free Bed Rehabilitation Hospital
    Grand Rapids, Michigan 49503, United States
  • Beaumont Hospital, Grosse Pointe
    Grosse Pointe, Michigan 48230, United States
  • Michigan Center of Medical Research
    Grosse Pointe, Michigan 48334, United States
  • Rusk Rehabilitation Center
    Columbia, Missouri 65203-3248, United States
  • Wr-Crcn, Llc
    Las Vegas, Nevada 89106, United States
  • Cooper University Health Care
    Cherry Hill, New Jersey 08003, United States
  • New York University
    New York, New York 10016, United States
  • Weill Cornell Medicine Clinical and Translational Science Center
    New York, New York 10065, United States
  • North Suffolk Neurology
    Port Jefferson, New York 11725, United States
  • Mayo Clinic
    Rochester, New York 55905, United States
  • Sunnyview Rehabilitation Hospital
    Schenectady, New York 12308, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • Cleveland Clinic - Neurological Institute
    Cleveland, Ohio 44195, United States
  • MossRehab - Einstein Medical Center
    Elkins Park, Pennsylvania 20010, United States
  • Penn State Health Physical Medicine and Rehabilitation - Neurology
    Hershey, Pennsylvania 17033, United States
  • University of Pittsburgh Medical Center (UPMC)
    Pittsburgh, Pennsylvania 15213, United States
  • Aether Medicine
    Wayne, Pennsylvania 19087, United States
  • Siskin Hospital for Rehabilitation - Neurology
    Chattanooga, Tennessee 37403, United States
  • The Vanderbilt Clinic
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • TIRR Memorial Hermann Research Center
    Houston, Texas 77030, United States
  • UT Health San Antonio
    San Antonio, Texas 78229, United States
  • Texas Institute for Neurological Disorders
    Sherman, Texas 75093, United States
  • University of Utah School of Medicine
    Salt Lake City, Utah 84132, United States
  • Carilion Clinic Institute of Orthopaedics and Neurosciences
    Roanoke, Virginia 24016, United States
  • MedStar National Rehabilitation Network
    Columbia, Washington 20010, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
  • Medical College of Wisconsin - Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Lawson Health Research Institute
    London, Ontario N6C 5J1, Canada
  • Moncton Hospital
    Moncton, E1C 6Z8, Canada
  • Genge Partners
    Montreal, H3A 2B4, Canada
  • Victoria General Hospital
    Victoria, V9A 3P2, Canada
  • Centre Les Capucins
    Angers, 49100, France
  • Hôpital Pellegrin CHU Bordeaux
    Bordeaux, 33000, France
  • Hopital Sud
    Échirolles, 38434, France
  • Hôpital d'Instruction des Armées Laveran
    Marseille, 13384, France
  • Hôpital Saint-Jacques (CHU Nantes)
    Nantes, 44000, France
  • Hopital Archet (CHU de Nice)
    Nice, 06202, France
  • Hopital Fernand Widal
    Paris, 75010, France
  • Centre Mutualiste de Rééducation et de Réadaptation Fonction
    Ploemeur, France
  • Hôpital Jean Bernard (CHU Poitiers)
    Poitiers, 86000, France
  • Hôpital Pontchaillou (CHU Rennes)
    Rennes, 35033, France
  • Pole Saint Helier
    Rennes, 35043, France
  • Centre de Perharidy
    Roscoff, 29680, France
  • Centre Hospitalier de Saint-Amand-les-Eaux
    Saint-Amand-les-Eaux, 59230, France
  • Centre Hospitalier de Saint Amand Montrond
    Saint-Amand-Montrond, 18200, France
  • Hopital Henry Gabrielle (HCL)
    Saint-Genis-Laval, 69230, France
  • Hopitaux Universitaires De Strasbourg
    Strasbourg, 67091, France
  • Hopital de Rangueil
    Toulouse, 31059, France
  • University of Puerto Rico
    Santurce, Puerto Rico 00912, Puerto Rico
09

References and documents

Publications

  • Esquenazi A, Wein TH, Verduzco-Gutierrez M, Ayyoub Z, Page S, Harding S, Maisonobe P, Beneteau M, Patel A; DIRECTION study group. A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity. Adv Ther. 2026 May 20. doi: 10.1007/s12325-026-03635-y. Online ahead of print. PubMed 42159955 ↗
  • Esquenazi A, Ayyoub Z, Verduzco-Gutierrez M, Maisonobe P, Otto J, Patel AT. AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol. Adv Ther. 2021 Nov;38(11):5623-5633. doi: 10.1007/s12325-021-01896-3. Epub 2021 Sep 25. PubMed 34562231 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Aug 2025, 50 months.

Results were first posted in Jul 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2021
First posted
Jun 23, 2021
StartActual
Jun 23, 2021
Primary completionActual
Aug 26, 2025
CompletionActual
Aug 26, 2025
Results first posted
Jul 9, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04936542
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Jun 23, 2021
Primary completion
Aug 26, 2025
Completion
Aug 26, 2025
Results posted
Jul 9, 2026
Last update
Jul 9, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Botulinum toxin type A · Onabotulinum toxin A

Start the discussion